The EPIC Study showed that administration of
pimobendan resulted in a 15 ‑ month delay in onset of clinical signs of CHF, cardiac ‑ related death, or euthanasia compared with dogs receiving placebo.
The EPIC Study showed that administration of
pimobendan resulted in a 15 ‑ month delay in time to primary endpoint compared with dogs receiving placebo.
Not exact matches
These encouraging
results led us to believe that
pimobendan could be effective in preclinical mitral valve disease and that the investigation of this through the EPIC Study was useful and worthwhile.
Other clinical studies conducted to evaluate the effects of
pimobendan have shown positive
results, which have subsequently led to the appropriate treatment of dogs worldwide.
As a balanced vasodilator,
pimobendan dilates both veins and arteries
resulting in a reduction in preload and afterload.
Pimobendan is proven to decrease preload and afterload, and this, in combination with pimobendan's inotropic properties, may result in a reduction in cardiac size and filling pressures in dogs with significant cardiac remodelling secondar
Pimobendan is proven to decrease preload and afterload, and this, in combination with
pimobendan's inotropic properties, may result in a reduction in cardiac size and filling pressures in dogs with significant cardiac remodelling secondar
pimobendan's inotropic properties, may
result in a reduction in cardiac size and filling pressures in dogs with significant cardiac remodelling secondary to MMVD.
Recent
results from the EPIC Study, however, show that
pimobendan, when administered to dogs in stage B2 — before clinical signs of heart failure appear — succeeded in delaying the onset of CHF.
Groundbreaking
results of the EPIC (Evaluation of
Pimobendan In dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history, are now published.
This license extension follows the
results of a clinical trial — the so called EPIC trial — which studied the effect of
pimobendan (the active ingredient in...